These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18045202)

  • 1. Design, synthesis and pharmacological evaluation of HIV-1 reverse transcriptase inhibition of new indolin-2-ones.
    Boechat N; Kover WB; Bongertz V; Bastos MM; Romeiro NC; Azevedo ML; Wollinger W
    Med Chem; 2007 Nov; 3(6):533-42. PubMed ID: 18045202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain.
    Cocuzza AJ; Chidester DR; Cordova BC; Jeffrey S; Parsons RL; Bacheler LT; Erickson-Viitanen S; Trainor GL; Ko SS
    Bioorg Med Chem Lett; 2001 May; 11(9):1177-9. PubMed ID: 11354371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Murugesan V; Makwana N; Suryawanshi R; Saxena R; Tripathi R; Paranjape R; Kulkarni S; Katti SB
    Bioorg Med Chem; 2014 Jun; 22(12):3159-70. PubMed ID: 24794742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new vinyl selenone-based domino approach to spirocyclopropyl oxindoles endowed with anti-HIV RT activity.
    Palomba M; Rossi L; Sancineto L; Tramontano E; Corona A; Bagnoli L; Santi C; Pannecouque C; Tabarrini O; Marini F
    Org Biomol Chem; 2016 Feb; 14(6):2015-24. PubMed ID: 26754878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hit optimization studies of 3-hydroxy-indolin-2-one analogs as potential anti-HIV-1 agents.
    Chander S; Tang CR; Penta A; Wang P; Bhagwat DP; Vanthuyne N; Albalat M; Patel P; Sankpal S; Zheng YT; Sankaranarayanan M
    Bioorg Chem; 2018 Sep; 79():212-222. PubMed ID: 29775947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
    Monforte AM; Logoteta P; Ferro S; De Luca L; Iraci N; Maga G; Clercq ED; Pannecouque C; Chimirri A
    Bioorg Med Chem; 2009 Aug; 17(16):5962-7. PubMed ID: 19616956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
    Patel M; McHugh RJ; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Ko SS
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3221-4. PubMed ID: 10576692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
    Corbett JW; Ko SS; Rodgers JD; Gearhart LA; Magnus NA; Bacheler LT; Diamond S; Jeffrey S; Klabe RM; Cordova BC; Garber S; Logue K; Trainor GL; Anderson PS; Erickson-Viitanen SK
    J Med Chem; 2000 May; 43(10):2019-30. PubMed ID: 10821714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of nonnucleoside HIV reverse transcriptase inhibitors.
    Tucker TJ; Lumma WC; Culberson JC
    Methods Enzymol; 1996; 275():440-72. PubMed ID: 9026654
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Yan ZH; Wu HQ; Chen WX; Wu Y; Piao HR; He QQ; Chen FE; De Clercq E; Pannecouque C
    Bioorg Med Chem; 2014 Jun; 22(12):3220-6. PubMed ID: 24794751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents.
    Barreca ML; Balzarini J; Chimirri A; De Clercq E; De Luca L; Höltje HD; Höltje M; Monforte AM; Monforte P; Pannecouque C; Rao A; Zappalà M
    J Med Chem; 2002 Nov; 45(24):5410-3. PubMed ID: 12431069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
    Wu B; Kuhen K; Ngoc Nguyen T; Ellis D; Anaclerio B; He X; Yang K; Karanewsky D; Yin H; Wolff K; Bieza K; Caldwell J; He Y
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3430-3. PubMed ID: 16632349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.
    Gawali R; Trivedi J; Bhansali S; Bhosale R; Sarkar D; Mitra D
    Eur J Med Chem; 2018 Sep; 157():310-319. PubMed ID: 30099253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
    O'Meara JA; Jakalian A; LaPlante S; Bonneau PR; Coulombe R; Faucher AM; Guse I; Landry S; Racine J; Simoneau B; Thavonekham B; Yoakim C
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3362-6. PubMed ID: 17451954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.
    He Y; Chen F; Yu X; Wang Y; De Clercq E; Balzarini J; Pannecouque C
    Bioorg Chem; 2004 Dec; 32(6):536-48. PubMed ID: 15530994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Design, synthesis and biologic evaluation of diarylbenzimidazole derivatives as novel HIV-1 non-nucleoside reverse transcriptase inhibitors].
    Qin BJ; Zhou T; Lu H; Jiang SB; Xie L
    Yao Xue Xue Bao; 2009 Nov; 44(11):1233-43. PubMed ID: 21355324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Efavirenz Derivatives and 1,2,3-Triazolyl-phosphonates as Inhibitors of Reverse Transcriptase of HIV-1.
    Costa CCP; Boechat N; Bastos MM; da Silva FC; Marttorelli A; Souza TML; Baptista MS; Hoelz LVB; Cafffarena ER
    Curr Top Med Chem; 2018; 18(17):1494-1505. PubMed ID: 30370848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and anti-HIV-1 activities of new pyrimido[5,4-b]indoles.
    Merino I; Monge A; Font M; Martínez de Irujo JJ; Alberdi E; Santiago E; Prieto I; Lasarte JJ; Sarobe P; Borrás F
    Farmaco; 1999 Apr; 54(4):255-64. PubMed ID: 10384720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.
    Hunter R; Muhanji CI; Hale I; Bailey CM; Basavapathruni A; Anderson KS
    Bioorg Med Chem Lett; 2007 May; 17(9):2614-7. PubMed ID: 17317163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.